Iovance Biotherapeutics (IOVA) News Today $3.62 -0.01 (-0.14%) As of 12:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 12-Month Low - Here's What HappenedIovance Biotherapeutics (NASDAQ:IOVA) Reaches New 12-Month Low - Here's What HappenedMarch 28 at 5:13 AM | marketbeat.comContrasting Qiagen (NYSE:QGEN) and Iovance Biotherapeutics (NASDAQ:IOVA)March 27 at 2:07 AM | americanbankingnews.comIs Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) The Top Penny Stock That Will Skyrocket?March 25 at 9:54 PM | msn.comZacks Research Analysts Lower Earnings Estimates for IOVAMarch 25 at 1:13 AM | americanbankingnews.comEquities Analysts Offer Predictions for IOVA Q1 EarningsIovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Investment analysts at Zacks Research cut their Q1 2025 earnings per share (EPS) estimates for shares of Iovance Biotherapeutics in a research note issued on Wednesday, March 19th. Zacks Research analyst S. Ganoria now anticipates that tMarch 24, 2025 | marketbeat.comIovance Biotherapeutics (NASDAQ:IOVA) Hits New 1-Year Low - Should You Sell?March 23, 2025 | americanbankingnews.com1 Stock Worth Buying Near Its 52-Week Low, According to Wall StreetMarch 22, 2025 | fool.comIovance Biotherapeutics (NASDAQ:IOVA) Hits New 52-Week Low - What's Next?Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 12-Month Low - What's Next?March 22, 2025 | marketbeat.com3 Growth Stocks Wall Street Might Be Sleeping On -- But I'm NotMarch 22, 2025 | fool.comResearch Analysts Offer Predictions for IOVA FY2027 EarningsIovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Zacks Research issued their FY2027 earnings per share (EPS) estimates for shares of Iovance Biotherapeutics in a report issued on Wednesday, March 19th. Zacks Research analyst S. Ganoria expects that the biotechnology company will post eMarch 22, 2025 | marketbeat.comIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)March 21, 2025 | globenewswire.comRaymond James Financial Inc. Purchases New Shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)Raymond James Financial Inc. purchased a new stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,563,296 shares of the biotechnology company'sMarch 21, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Increases Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)Charles Schwab Investment Management Inc. lifted its stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 4.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,989,340 shares of the biotechnology company's stockMarch 21, 2025 | marketbeat.comIovance Biotherapeutics Likely to Add Hundreds of New Jobs At Philadelphia Navy YardMarch 20, 2025 | msn.com124,449 Shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Purchased by Haven Capital Group Inc.Haven Capital Group Inc. bought a new stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 124,449 shares of the biotechnology company's stock, valuedMarch 19, 2025 | marketbeat.comIovance: The Company Makes It Hard To Estimate Revenue GrowthMarch 18, 2025 | seekingalpha.comIs Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) the Most Oversold Penny Stocks to Buy According to Analysts?March 18, 2025 | msn.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Recommendation of "Moderate Buy" by BrokeragesMarch 18, 2025 | americanbankingnews.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Rating of "Moderate Buy" from BrokeragesIovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eight analysts that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and seven have assigned a buy ratingMarch 18, 2025 | marketbeat.comIovance Biotherapeutics (IOVA) Receives a Buy from Stifel NicolausMarch 17, 2025 | markets.businessinsider.comIovance Biotherapeutics (NASDAQ:IOVA) Sets New 12-Month Low - Time to Sell?Iovance Biotherapeutics (NASDAQ:IOVA) Hits New 1-Year Low - Time to Sell?March 14, 2025 | marketbeat.comTruist Financial Reaffirms Their Buy Rating on Exelixis (EXEL)March 13, 2025 | markets.businessinsider.comIovance expects to add hundreds of jobs at Navy Yard cell therapy centerMarch 12, 2025 | bizjournals.comStifel Nicolaus Remains a Hold on Atara Biotherapeutics (ATRA)March 12, 2025 | markets.businessinsider.comDown Nearly 80% From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up?March 12, 2025 | msn.comIovance Biotherapeutics (NASDAQ:IOVA) Reaches New 52-Week Low - Time to Sell?Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 52-Week Low - What's Next?March 8, 2025 | marketbeat.comMelanoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and CompaniesMarch 6, 2025 | theglobeandmail.comIovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 5.8% After Analyst DowngradeIovance Biotherapeutics (NASDAQ:IOVA) Shares Down 5.8% on Analyst DowngradeMarch 5, 2025 | marketbeat.comIovance Biotherapeutics (NasdaqGM:IOVA) Stock Dips 27% Despite Reaffirmed 2025 Earnings GuidanceMarch 4, 2025 | finance.yahoo.comQ1 Earnings Estimate for IOVA Issued By HC WainwrightIovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 EPS estimates for Iovance Biotherapeutics in a report issued on Friday, February 28th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will post earninMarch 4, 2025 | marketbeat.comIovance Biotherapeutics price target lowered to $15 from $25 at TruistMarch 3, 2025 | markets.businessinsider.comTruist Financial Cuts Iovance Biotherapeutics (NASDAQ:IOVA) Price Target to $15.00Truist Financial decreased their target price on Iovance Biotherapeutics from $25.00 to $15.00 and set a "buy" rating for the company in a research note on Monday.March 3, 2025 | marketbeat.comIovance Biotherapeutics price target lowered to $30 from $34 at ChardanMarch 3, 2025 | markets.businessinsider.comThe Goldman Sachs Group Has Lowered Expectations for Iovance Biotherapeutics (NASDAQ:IOVA) Stock PriceThe Goldman Sachs Group lowered their price target on Iovance Biotherapeutics from $22.00 to $19.00 and set a "buy" rating for the company in a report on Monday.March 3, 2025 | marketbeat.comIovance Biotherapeutics (NASDAQ:IOVA) Price Target Lowered to $30.00 at Chardan CapitalChardan Capital dropped their price target on shares of Iovance Biotherapeutics from $34.00 to $30.00 and set a "buy" rating on the stock in a research report on Monday.March 3, 2025 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: HCA Healthcare (HCA), Kura Oncology (KURA)March 3, 2025 | markets.businessinsider.comResearch Analysts Set Expectations for IOVA Q1 EarningsIovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - HC Wainwright issued their Q1 2025 earnings estimates for shares of Iovance Biotherapeutics in a report issued on Friday, February 28th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will earn ($0.23) per shMarch 3, 2025 | marketbeat.comStock Traders Buy High Volume of Call Options on Iovance Biotherapeutics (NASDAQ:IOVA)Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) was the target of some unusual options trading on Friday. Traders purchased 20,884 call options on the company. This represents an increase of approximately 94% compared to the average daily volume of 10,787 call options.March 1, 2025 | marketbeat.comIovance Biotherapeutics (NASDAQ:IOVA) Sets New 52-Week Low Following Analyst DowngradeIovance Biotherapeutics (NASDAQ:IOVA) Sets New 52-Week Low After Analyst DowngradeMarch 1, 2025 | marketbeat.comIovance Biotherapeutics Full Year 2024 Earnings: EPS Misses ExpectationsMarch 1, 2025 | finance.yahoo.comRobert W. Baird Cuts Iovance Biotherapeutics (NASDAQ:IOVA) Price Target to $20.00Robert W. Baird dropped their price objective on shares of Iovance Biotherapeutics from $24.00 to $20.00 and set an "outperform" rating for the company in a report on Friday.March 1, 2025 | marketbeat.comIovance Biotherapeutics (NASDAQ:IOVA) Price Target Lowered to $6.00 at Piper SandlerPiper Sandler dropped their target price on Iovance Biotherapeutics from $7.50 to $6.00 and set a "neutral" rating on the stock in a research report on Friday.March 1, 2025 | marketbeat.comIovance Biotherapeutics (NASDAQ:IOVA) Given "Buy" Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $32.00 target price on shares of Iovance Biotherapeutics in a report on Friday.March 1, 2025 | marketbeat.comIovance Biotherapeutics (NASDAQ:IOVA) Releases Earnings Results, Hits ExpectationsIovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) released its earnings results on Thursday. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.26). Iovance Biotherapeutics had a negative return on equity of 58.43% and a negative net margin of 451.25%.February 28, 2025 | marketbeat.comIovance Biotherapeutics (NASDAQ:IOVA) Announces Quarterly Earnings Results, Meets EstimatesIovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.26). Iovance Biotherapeutics had a negative return on equity of 58.43% and a negative net margin of 451.25%.February 28, 2025 | marketbeat.comForecasting The Future: 4 Analyst Projections For Iovance BiotherapeuticsFebruary 28, 2025 | benzinga.comIovance Biotherapeutics price target lowered to $20 from $24 at BairdFebruary 28, 2025 | markets.businessinsider.comIovance Shares Fall After Sales of Cancer Drug Miss EstimateFebruary 28, 2025 | marketwatch.comIovance's Q4: Execution Risks Mount As Infusion Growth Slows (Rating Downgrade)February 28, 2025 | seekingalpha.comIovance Biotherapeutics, Inc. (IOVA) Q4 2024 Earnings Call TranscriptFebruary 27, 2025 | seekingalpha.com Remove Ads Get Iovance Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter. Email Address IOVA Media Mentions By Week IOVA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IOVA News Sentiment▼0.440.78▲Average Medical News Sentiment IOVA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IOVA Articles This Week▼177▲IOVA Articles Average Week Remove Ads Get Iovance Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PTC Therapeutics News Today Avidity Biosciences News Today Arcellx News Today Organon & Co. News Today Zai Lab News Today SpringWorks Therapeutics News Today Ultragenyx Pharmaceutical News Today Akero Therapeutics News Today Alvotech News Today Rhythm Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IOVA) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | SponsoredTrump… a socialist? Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs Trump Secretly Pumping Up Elon’s New AI Venture?President Trump just bought a Tesla - right in front of the White House. But what most investors don't real...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Iovance Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IOVA Stock Free IOVA Stock Alerts